Global Anti-Obesity Medical Devices Market Forecast, 2026-2036 | Market to Reach $4.41 Billion as Endoscopic, Swallowable, and Post-GLP-1 Solutions Drive Growth
Dublin, Oct. 30, 2026 (GLOBE NEWSWIRE) -- "Anti-Obesity Medical Devices Market - Global Forecast to 2036" has been added to ResearchAndMarkets.com's offering.
The global anti-obesity medical devices market was valued at USD 2.40 billion in 2025 and is estimated to reach USD 2.51 billion in 2026. The market is projected to expand to USD 4.41 billion by 2036, growing at a CAGR of 5.8% during the 2026-2036 forecast period.
The report provides an in-depth assessment of the obesity treatment gap, clinical evidence, device technologies, regulatory pathways, reimbursement, pricing, product pipelines, competitive positioning, and the impact of GLP-1 medications on procedure demand. It covers surgical devices, endoscopic systems, intragastric balloons, gastric bands, neuromodulation devices, and ingestible & oral devices. Medicines and consumer slimming products not regulated as medical devices are excluded.
Market Growth Drivers and Challenges
Demand is supported by the large population living with obesity and the low proportion receiving treatment. According to the World Health Organization, 890 million adults were living with obesity in 2022. The American Society for Metabolic and Bariatric Surgery recorded 270,089 U.S. bariatric operations in 2023, while less than 1% of eligible patients undergo surgery annually.
Updated eligibility guidelines, durable clinical outcomes, and approvals for less invasive technologies are expected to support market expansion. The 2022 ASMBS and IFSO guidelines lowered surgical eligibility to a BMI of 35 regardless of comorbidities and to 30 for patients with metabolic disease. A 51,085-patient study presented at the ASMBS 2025 meeting reported 24% total weight loss two years after sleeve gastrectomy or gastric bypass, compared with 4.7% among patients prescribed GLP-1 drugs for at least six months.
GLP-1 medications remain the market's primary restraint. Procedures at accredited U.S. centers declined to slightly more than 177,000 in 2024, approximately 23% below the 2022 peak. U.S. intragastric balloon procedures also fell from 4,358 in 2022 to 1,461 in 2023. Limited reimbursement for balloons and endoscopic sleeve gastroplasty, previous FDA safety communications, and the financial vulnerability of specialist developers continue to affect adoption.
Weight maintenance following GLP-1 discontinuation represents a significant opportunity. A JAMA Network Open study involving more than 125,000 U.S. patients found that 64.8% of patients without diabetes discontinued GLP-1 treatment within one year. Clinical evidence also indicates substantial weight regain after treatment ends. These findings are encouraging investment in device-drug combinations, maintenance indications, digital support, and muscle-preservation programs.
Segment Outlook
Regional Market Opportunities
North America is expected to remain the largest anti-obesity medical devices market in 2026. The region benefits from high procedure volumes, established reimbursement for bariatric surgery, leading medical technology companies, and early regulatory approvals. Europe is also expected to hold a significant share, supported by publicly funded bariatric surgery programs and its established role as a launch market for obesity devices.
Asia-Pacific is projected to register the highest CAGR through 2036 due to rising obesity and diabetes prevalence, lower BMI eligibility thresholds, expanding surgical capacity, and increasing adoption of endoscopic procedures. China and India are developing bariatric programs, while the high cost of branded GLP-1 medications may strengthen demand for device-based treatment. Brazil and Mexico lead adoption in Latin America, while Saudi Arabia, Kuwait, Qatar, and the UAE are supporting growth across the Middle East & Africa. Turkiye remains an important destination for bariatric medical tourism.
Competitive Landscape
Large medical technology companies dominate surgical stapling, energy devices, access systems, and robotics, while specialist developers compete across balloons, endoscopic platforms, duodenal therapies, and ingestible products. Competitive performance depends on clinical efficacy, durability, safety, reimbursement, ease of use, and compatibility with medication-based care.
Important strategic developments include Boston Scientific's 2023 acquisition of Apollo Endosurgery, the 2026 FDA approval of Allurion's swallowable balloon, Allurion's move toward combining its system with low-dose GLP-1 therapy, and Fractyl Health's pivotal program evaluating weight maintenance after tirzepatide treatment.
Companies profiled include Medtronic plc, Johnson & Johnson MedTech (Ethicon), Intuitive Surgical, Inc., Teleflex Incorporated, Applied Medical Resources Corporation, CONMED Corporation, Boston Scientific Corporation, Olympus Corporation, Cook Medical LLC, Endo Tools Therapeutics S.A., Allurion Technologies, Inc., Fractyl Health, Inc., ReShape Lifesciences Inc., GI Dynamics, Inc., and Spatz Medical.
Strategic Value of the Report
Key Topics Covered
1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency and Limitations
1.3.1. Currency
1.3.2. Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Data Collection & Validation Process
2.2.1. Secondary Research
2.2.2. Primary Research & Validation
2.2.2.1. Primary Interviews with Industry Experts
2.2.2.2. Country-/Region-Level Analysis
2.3. Market Estimation
2.3.1. Bottom-Up Approach (Procedure Volume x Device Utilization x Price)
2.3.2. Top-Down Approach (Share of Surgical and Endoscopic Device Revenues)
2.3.3. Forecast Methodology
2.4. Data Triangulation
2.5. Assumptions
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.1.1. Large and Undertreated Population Living with Obesity
4.2.1.2. Durable Weight Loss with Device-Based Treatment
4.2.1.3. Regulatory Approvals Expanding Less Invasive Options
4.2.2. Restraints
4.2.2.1. Substitution of GLP-1 Medications for Procedures
4.2.2.2. Commercial Fragility of Non-Surgical Device Companies
4.2.2.3. Limited Reimbursement for Endoscopic and Non-Surgical Therapies
4.2.2.4. Safety Concerns and Regulatory Scrutiny
4.2.3. Opportunities
4.2.3.1. Weight Maintenance After GLP-1 Discontinuation
4.2.3.2. Device and Drug Combination Therapies
4.2.3.3. Rising Procedure Volumes in Emerging Markets
4.2.4. Challenges
4.2.4.1. Demonstrating Durable Outcomes Relative to Medications and Surgery
4.2.4.2. Integrating Devices with Pharmacotherapy
4.2.4.3. Generating Evidence for Post-Medication Weight Maintenance
4.2.4.4. Uncertainty in Procedure Volumes
4.3. Key Trends
4.3.1. From Surgery-Only Treatment to a Multi-Modal Obesity Care Continuum
4.3.2. Rise of Endoscopic and Swallowable Devices
4.3.3. Shift Toward Gastric Bypass and Revisional Surgery
4.3.4. Integration of Digital and Muscle-Focused Support Platforms
4.4. Obesity Treatment Landscape
4.4.1. Epidemiology and Treatment Gap
4.4.2. Pharmacotherapy and Its Impact on Device Demand
4.4.3. Positioning of Devices Across the Care Continuum
4.5. Technology Landscape
4.5.1. Surgical Stapling, Energy, and Robotics
4.5.2. Endoscopic Suturing and Plication
4.5.3. Intragastric Balloons (Endoscopic and Swallowable)
4.5.4. Duodenal Mucosal Resurfacing and Endoscopic Liners
4.5.5. Neuromodulation and Electrical Stimulation
4.5.6. Ingestible and Oral Devices
4.6. Clinical Evidence Analysis
4.6.1. Surgery Versus Pharmacotherapy
4.6.2. Endoscopic and Balloon Pivotal Trials
4.6.3. Post-GLP-1 Weight Maintenance Studies
4.7. Regulatory and Reimbursement Landscape
4.7.1. FDA Pathways for Obesity Devices
4.7.2. CE Marking and EU Medical Device Regulation
4.7.3. Coverage for Surgical and Non-Surgical Procedures
4.8. Pipeline Analysis
4.9. Pricing Analysis
4.10. Value Chain Analysis
4.11. Porter's Five Forces Analysis
5. Anti-Obesity Medical Devices Market, by Device Type
5.1. Introduction
5.2. Surgical Devices
5.2.1. Stapling Devices
5.2.2. Energy Devices
5.2.3. Access & Suturing Devices
5.2.4. Robotic Instruments & Accessories
5.3. Endoscopic Devices
5.3.1. Endoscopic Suturing & Plication Systems
5.3.2. Duodenal Mucosal Resurfacing Systems
5.3.3. Endoscopic Liners
5.4. Intragastric Balloons
5.4.1. Endoscopically Placed Balloons
5.4.2. Swallowable Balloons
5.5. Gastric Bands
5.6. Neuromodulation Devices
5.7. Ingestible & Oral Devices
6. Anti-Obesity Medical Devices Market, by Approach
6.1. Introduction
6.2. Surgical
6.3. Endoscopic
6.4. Swallowable & Non-Invasive
7. Anti-Obesity Medical Devices Market, by Treatment Intent
7.1. Introduction
7.2. Primary Weight Loss
7.3. Weight Maintenance After Pharmacotherapy
7.4. Revisional Treatment
7.5. Combination Therapy
8. Anti-Obesity Medical Devices Market, by BMI Category
8.1. Introduction
8.2. BMI 27.5 to 34.9
8.3. BMI 35 to 39.9
8.4. BMI 40 and Above
9. Anti-Obesity Medical Devices Market, by End User
9.1. Introduction
9.2. Hospitals
9.3. Ambulatory Surgery Centers
9.4. Specialty Obesity & Gastroenterology Clinics
10. Anti-Obesity Medical Devices Market, by Geography
10.1. Introduction
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. U.K.
10.3.2. France
10.3.3. Germany
10.3.4. Italy
10.3.5. Spain
10.3.6. Belgium
10.3.7. Nordic Countries
10.3.8. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. India
10.4.3. Japan
10.4.4. South Korea
10.4.5. Australia
10.4.6. Southeast Asia
10.4.7. Rest of Asia-Pacific
10.5. Latin America
10.5.1. Brazil
10.5.2. Mexico
10.5.3. Colombia
10.5.4. Argentina
10.5.5. Chile
10.5.6. Rest of Latin America
10.6. Middle East & Africa
10.6.1. Saudi Arabia
10.6.2. Kuwait
10.6.3. UAE & Qatar
10.6.4. Turkiye
10.6.5. Egypt
10.6.6. South Africa
10.6.7. Rest of Middle East & Africa
11. Competitive Landscape
11.1. Overview
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Competitive Dashboard
11.4.1. Industry Leaders
11.4.2. Market Differentiators
11.4.3. Vanguards
11.4.4. Emerging Companies
11.5. Market Share/Rank Analysis, by Key Player (2025)
12. Company Profiles
Business Overview, Financial Overview, Product Portfolio, Pipeline, Strategic Developments, and SWOT Analysis
Surgical Device and Robotics Leaders
12.1. Medtronic plc
12.2. Johnson & Johnson MedTech (Ethicon)
12.3. Intuitive Surgical, Inc.
12.4. Teleflex Incorporated
12.5. Applied Medical Resources Corporation
12.6. CONMED Corporation
Endoscopy Companies
12.7. Boston Scientific Corporation
12.8. Olympus Corporation
12.9. Cook Medical LLC
12.10. Endo Tools Therapeutics S.A.
Specialist Obesity Device Developers
12.11. Allurion Technologies, Inc.
12.12. Fractyl Health, Inc.
12.13. ReShape Lifesciences Inc.
12.14. GI Dynamics, Inc.
12.15. Spatz Medical
13. Appendix
13.1. Related Reports
13.2. Customization Options
List of Tables [372]
List of Figures [49]
For more information about this report visit https://www.researchandmarkets.com/r/qie741
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.